1. Pink Sheet
  2. >>Geography
  3. >>Latin America

Mexico To Expand Recognition Of International GMP Certificates For Biologic Medicines

 
• By Francesca Bruce

Moves to widen GMP certificate recognition are in line with World Health Organization recommendations on Good Reliance Practices and with the Mexican government’s strategy for regulatory certainty for the pharmaceutical sector, says the country’s drugs regulator.

drug manufacturing
Mexico widens GMP Certificate Recognition • Source: Shutterstock

Mexico’s medicines regulator, Cofepris, is now recognizing good manufacturing practice certificates for manufacturers producing biologic medicines in other countries, including new innovative products and biosimilars.

Specifically, Cofepris will recognize GMP certificates issued by authorities accredited by the World Health Organization (WHO)/Pan American Health Organization (PAHO)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Latin America

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 
• By Francesca Bruce

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

Brazil Could Look To Germany, UK And Australia For ATMP Drug Pricing Rules

 
• By Francesca Bruce

There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.

Argentina Speeds Up Market Access Process

 
• By Francesca Bruce

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

 
• By Francesca Bruce

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.

More from Geography

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.